LLY

915.4

+2.86%↑

JNJ

243.28

+0.21%↑

ABBV

216.93

+1.8%↑

NVS

151.84

+0.98%↑

MRK

120.12

+1.68%↑

LLY

915.4

+2.86%↑

JNJ

243.28

+0.21%↑

ABBV

216.93

+1.8%↑

NVS

151.84

+0.98%↑

MRK

120.12

+1.68%↑

LLY

915.4

+2.86%↑

JNJ

243.28

+0.21%↑

ABBV

216.93

+1.8%↑

NVS

151.84

+0.98%↑

MRK

120.12

+1.68%↑

LLY

915.4

+2.86%↑

JNJ

243.28

+0.21%↑

ABBV

216.93

+1.8%↑

NVS

151.84

+0.98%↑

MRK

120.12

+1.68%↑

LLY

915.4

+2.86%↑

JNJ

243.28

+0.21%↑

ABBV

216.93

+1.8%↑

NVS

151.84

+0.98%↑

MRK

120.12

+1.68%↑

Home・Akcijų sąrašas・Design Therapeutics Inc

Design Therapeutics Inc

Atidarymo kaina

10.72 2.68

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

10.14

Max

10.78

Pagrindiniai rodikliai
By Trading Economics
Pajamos	1M -16M
Darbuotojai	54
EBITDA	-6M -23M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+47.2% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-05-05

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	44M 627M
Ankstesnė atidarymo kaina	8.04
Ankstesnė uždarymo kaina	10.72

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

3.26 / 3.63 Palaikymas ir pasipriešinimas

Design Therapeutics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-03-30 23:15; UTC

Svarbiausios naujienos

U.K. Shoppers Paid a Little More This Month But Worse May yet Lie Ahead

2026-03-30 22:36; UTC

Svarbiausios naujienos

Australian Government Rules Out Boots on the Ground in the Middle East

2026-03-30 22:13; UTC

Įsigijimai, susijungimai, perėmimai

Sun Life Financial Agrees to Buy Bell Partners for $350 Million

2026-03-30 21:00; UTC

Uždarbis

Aktis Oncology Gets FDA Clearance for Phase 1 Billion Trial of Tumor Treatment

2026-03-30 20:15; UTC

Svarbiausios naujienos

Fed's Williams: Middle-East Developments Have Added Significant Economic Uncertainty

2026-03-30 23:40; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-03-30 23:40; UTC

Rinkos pokalbiai

Nikkei May Decline on Higher Energy Cost Concerns -- Market Talk

2026-03-30 23:36; UTC

Rinkos pokalbiai

Gold Edges Lower Amid Divergent Signals on U.S.-Iran Talks -- Market Talk

2026-03-30 23:12; UTC

Rinkos pokalbiai

Alcoa Earnings Outlook Boosted by Market Disruptions -- Market Talk

2026-03-30 22:49; UTC

Rinkos pokalbiai

Fed's Williams: Core Inflation Forecast Is Little Changed -- Market Talk

2026-03-30 22:44; UTC

Rinkos pokalbiai

Fed's Williams: Risks to Both Sides of Dual Mandate Higher -- Market Talk

2026-03-30 22:43; UTC

Rinkos pokalbiai

Fed's Williams Says Focus Is on Inflation Expectations Being Well Anchored -- Market Talk

2026-03-30 22:42; UTC

Rinkos pokalbiai

South32 Should Go for Growth, Says New Bull -- Market Talk

2026-03-30 22:18; UTC

Rinkos pokalbiai

Paragon Care's Chances of Using Levy to Pass on Higher Costs `Close to Zero' -- Market Talk

2026-03-30 22:05; UTC

Rinkos pokalbiai

Northern Star's New Bull Argues Case for Asset Sales -- Market Talk

2026-03-30 21:58; UTC

Įsigijimai, susijungimai, perėmimai

Sun Life Financial Agrees to Buy Bell Partners for $350M

2026-03-30 21:39; UTC

Įsigijimai, susijungimai, perėmimai

Sun Life Sees 1Q Charge to Net of C$236M From BGO, Crescent Deals

2026-03-30 21:38; UTC

Įsigijimai, susijungimai, perėmimai

Sun Life: Completes Remaining Equity Interest Purchases of BGO, Crescent Capital

2026-03-30 21:36; UTC

Įsigijimai, susijungimai, perėmimai

Sun Life to Buy Fully Bell Partners for $350M >SLF.T

2026-03-30 21:33; UTC

Įsigijimai, susijungimai, perėmimai

Unilever Shareholders Expected to Own Two-Thirds of New Food Entity, Sources Say -- WSJ

2026-03-30 21:33; UTC

Įsigijimai, susijungimai, perėmimai

Unilever Nears Deal to Create $60 Billion Food Giant With McCormick -- WSJ

2026-03-30 21:33; UTC

Įsigijimai, susijungimai, perėmimai

Deal Could Be Announced As Soon As Tuesday, Sources Say -- WSJ

2026-03-30 21:33; UTC

Įsigijimai, susijungimai, perėmimai

Unilever Nears Cash-and-Stock Deal to Combine Food Business With McCormick, Sources Say -- WSJ

2026-03-30 21:33; UTC

Įsigijimai, susijungimai, perėmimai

Deal Set to Value Combined Food Business At Around $60B Including Debt, Sources Say -- WSJ

2026-03-30 21:25; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-03-30 21:25; UTC

Rinkos pokalbiai

Warehouse Showing Cost Discipline But Margin Goal at Risk -- Market Talk

2026-03-30 21:03; UTC

Įsigijimai, susijungimai, perėmimai

Sun Life: Completes Equity Interest Purchases of BGO and Crescent Cap, Announces Acquisition of Bell Partners, a Multifamily Real Estate Investment Manager

2026-03-30 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-03-30 20:09; UTC

Uždarbis

This Stock Looks Like a Solid AI Bet -- and Wall Street Hasn't Noticed Yet -- Barrons.com

2026-03-30 20:00; UTC

Svarbiausios naujienos

Fed's Williams: Middle-East Conflict 'Will Likely Boost Overall Inflation in Coming Months'

Akcijų palyginimas

Kainos pokytis

Design Therapeutics Inc Prognozė

Kainos tikslas

By TipRanks

47.2% į viršų

12 mėnesių prognozė

Vidutinis 15.5 USD 47.2%

Aukščiausias 18 USD

Žemiausias 14 USD

Remiantis 4 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Design Therapeutics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

4 ratings

Pirkti

Laikyti

Parduoti

Remiantis 4 analitikų, pateikusių Design Therapeutics Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

3.26 / 3.63Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

All events are bearish.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Design Therapeutics Inc

Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.